Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Cash from Investing Activities for 8 consecutive years, with $25.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 120.2% year-over-year to $25.3 million; the TTM figure through Mar 2026 stood at $28.9 million (down 74.49% YoY), while the FY2025 annual figure was -$121.4 million, down 165.64% from the prior year.
• Cash from Investing Activities declined to $25.3 million in Q1 2026 per BEAM's latest filing, from $108.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $126.3 million in Q4 2024 and bottomed at -$537.3 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$17.7 million across 5 years, with a median of $24.7 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 3186.85% — and 2024, when it surged 341.43%.
• Beam Therapeutics' Cash from Investing Activities stood at $113.4 million in 2022, then fell by 13.52% to $98.1 million in 2023, then increased by 28.73% to $126.3 million in 2024, then retreated by 14.15% to $108.4 million in 2025, then slumped by 76.69% to $25.3 million in 2026.
• Business Quant data shows BEAM's Cash from Investing Activities at $25.3 million in Q1 2026, $108.4 million in Q4 2025, and $65.7 million in Q3 2025.